By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA)’s Partner, Lexicon Pharma (LXRX), Announces Positive Results From TELESTAR Phase 3 Study Showing That Telotristat Etiprate Is Effective In The Treatment Of Carcinoid Syndrome Caused By Neuroendocrine Tumors Not Adequately Controlled By Somatostatin 8/3/2015 11:26:32 AM
Ipsen (IPN.PA): 2015 Half-Year Results 7/31/2015 7:57:33 AM
Ipsen (IPN.PA) Announces FDA Approval Of Dysport(Abobotulinumtoxina) For Injection In The Treatment Of Upper Limb Spasticity In Adults In The United States 7/17/2015 9:17:28 AM
Ipsen (IPN.PA) Provides An Update On 2020 Strategy And Outlook At Investor Day 7/2/2015 11:18:20 AM
Ipsen (IPN.PA) Initiates A Share Buyback Program 6/3/2015 8:50:48 AM
Ipsen (IPN.PA) Confirms Its Eligibility For PEA-PME 6/2/2015 12:39:13 PM
Combined Shareholders’ Meeting Of IPSEN S.A. Held On 27 May 2015 5/29/2015 11:27:16 AM
Ipsen (IPN.PA) Strengthens Its Presence In The Oncology Field With The Acquisition Of Octreopharm Sciences, A Company Developing Innovative Radiopharmaceuticals For The Diagnosis And Treatment Of Neuroendocrine Tumors 5/19/2015 11:01:50 AM
Ipsen (IPN.PA) Announces Data Presentations For Somatuline Depot (lanreotide) In Gastroenteropancreatic Neuroendocrine Tumors At ASCO Annual Meeting 5/14/2015 12:35:04 PM
Ipsen (IPN.PA) Reports Strong Sales Growth In Q1 2015 And Raises Guidance For The Year 4/29/2015 12:18:38 PM